Current evidence reveals stark divergence in miR-145s targets across urologic tumors (e.g., SOX11 vs. TAGLN2), underscoring the need for cross-cancer studies to distinguish conserved from context-dependent mechanisms. Here, TAGLN2 is linked to cancer.